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For a protein based drugs, including antibody based radiopharmaceuticals, a structural characterization is mandatory
before any possible start of a clinical trial. Vibrational spectroscopic techniques, as Fourier transform infrared (FTIR)
spectroscopy and Raman spectroscopy are one of the biophysical methods for structural characterization of proteins
because of their sensitivity to the composition and architecture of molecules.
Here we used vibrational spectroscopy to characterize three immunoconjugates of rituximab, intended for labeling with
radioisotope of choice (177Lu, 90Y and/or 68Ga).
Rituximab, conjugated with three different bifunctional
chelating agents (BFCAs), p-SCN-Bn-DOTA, p-SCN-Bn-
DTPA and 1B4M-DTPA in a form of lyophilized
preparations non-radioactive labeled with above
mentioned radioisotope analogues, was subjected to
characterization and determination of secondary
structure and quality parameters (purity, integrity,
fragmentation and aggregation of the antibody).
Based on the frequencies assigned for amide I, II and III bands, the studied formulations contain highest percentage of β-
sheet conformation (antiparallel and parallel) in the structure, followed by α-helices. Significant changes upon processes
of conjugation and lyophilization were not observed in comparison with spectra of native antibody.Vibrational
spectroscopic data allow detection of alterations in investigated protein models as well as rapid assessment of
conformational changes resulting from ligand binding, aggregation or macromolecular interactions. According to the
obtained spectra, it is important that we observed retaining of native structure of the antibody and no obvious
aggregation (the lowest band frequency detected was 1620 cm–1 with weak intensity) in all samples of lyophilizated
conjugates.
We investigated the application of vibrational spectroscopy in assessment of conformational changes during stress
conditions, as lyophilization and non-radioactive labeling are, using different rituximab-conjugates. The results are a good
foundation for further radiolabeling studies of the lyophilized formulations for possible therapeutic application.
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Fig.1. Comparison of ATR-IR spectra of rituximab (native antibody) and 
p-SCN-Bn-DOTA-rituximab in a form of lyophilized preparations.
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This research has been performed in the frames of the CRP, financed by the IAEA, titled: Establishment and standardization of a technology for
the productionof ready-to-usecold kit formulations for labelling DOTA-Rituximaband peptide-basedconjugateswith Lu-177and Y-90.
Fig.2. Raman spectra of three types of BFCA-rituximab conjugates
labeled with non-radioactive Y.
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